Triple reuptake inhibitors: Next-generation antidepressants

Primary Psychiatry

Volumn 15, Issue 4, 2008, Pages 50-56

  Liang, Yanqi ^a   Richelson, Elliott ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOHEXYL 3 (DIMETHYLAMINO) 2 NAPHTHALEN 2 YL)PROPAN 1 OL; 3 (METHYLAMINO) 2 (NAPHTHALEN 2 YL) 1 PHENYLPROPAN 1 OL; 3 (METHYLAMINO) 2 NAPHTHALEN 2 YL) 1 PHENYLPROPAN 1 OL; ANTIDEPRESSANT AGENT; DOPAMINE UPTAKE INHIBITOR; DOV 102677; DOV 216303; DULOXETINE; METHYLPHENIDATE; NOMIFENSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NS 2330; NS 2359; PAROXETINE; PRC 025; PRC 050; PRC 200 SS; PROPANOL; SEP 225289; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TESOFENSINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

DEPRESSION; DRUG STRUCTURE; HAMILTON SCALE; HUMAN; NERVOUS SYSTEM DEVELOPMENT; PARKINSON DISEASE; REVIEW; RISK FACTOR; SEXUAL DYSFUNCTION;

EID: 42249116187     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Schildkraut JJ. The catecholamine hypothesis of affective disorders: a review of supporting evidence. 1965. J Neuropsychiatry Clin Neurosci. 1995;7(4):524-533.
2. Richelson E. Interactions of antidepressants with neurotransmitter transporters and receptors and their clinical relevance. J Clin Psychiatry. 2003;64(suppl 13):5-12.
3. Richelson E. Action of antidepressant and other drugs on norepinephrine systems. In: Ordway GA, Schwartz MA, Frazer A, eds. Brain Norepinephrine: Neurobiology and Therapeutics. New York, NY Cambridge University Press; 2007:515.
4. Baldessarini R. Drugs and the treatment of psychiatric disorders-depression and mania. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996:431-459.
5. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F. Strategies for producing faster acting antidepressants. Drug Discov Today. 2005;10(8):578-585.
6. Nemeroff CB, Owens MJ. Treatment of mood disorders. Nat Neurosci. 2002;5(suppl):1068-1070.
7. Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry. 2001;62(suppl 15):12-17.
8. Lapiz MD, Zhao Z, Bondi CO, O'Donnell JM, Morilak DA. Blockade of autoreceptor-mediated inhibition of norepinephrine release by atipamezole is maintained after chronic reuptake inhibition. Int J Neuropsychopharmacol. 2007;10(6):827-833.
9. Invernizzi RW, Garattini S. Role of presynaptic alpha2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):819-827.
10. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995; 5(11):7539-7547.
11. Hunsberger JG, Newton SS, Bennett AH, et al. Antidepressant actions of the exercise-regulated gene VGF. Nat Med. 2007;13(12):1476-1482.
12. Thakker-Varia S, Krol JJ, Nettleton J, et al. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci. 2007;27(45):12156-12167.
13. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry. 2007;64(3):327-337.
14. Cassano P, Lattanzi L, Soldani F, et al. Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety. 2004;20(3):131-138.
15. Cassano P, Lattanzi L, Fava M, et al. Ropinirole in treatment-resistant depression: a 16-week pilot study. Can J Psychiatry. 2005;50(6):357-360.
16. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. "Broad spectrum" antidepressants: is more better for the treatment of depression? Life Sci. 2003;73(25):3175-3179.
17. Carlier PR, Lo MM, Lo PC, et al. Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett. 1998;8(5):487-492.
18. Van Kampen JM, Hagg T, Robertson HA. Induction of neurogenesis in the adult rat subventricular zone and neostriatum following dopamine D3 receptor stimulation. Eur J Neurosci. 2004;19(9):2377-2387.
19. D'Aquila PS, Collu M, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol. 2000;405(1-3):365-373.
20. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, text rev. Washington, DC: American Psychiatric Association; 2000.
21. Paizanis E, Hamon M, Lanfumey L. Hippocampal neurogenesis, depressive disorders, and antidepressant therapy. Neural Plast. 2007;2007:73754.
22. Sahay A, Hen R. Adult hippocampal neurogenesis in depression. Nat Neurosci. 2007;10(9):1110-1115.
23. Neill DB, Fenton H, Justice JB Jr. Increase in accumbal dopaminergic transmission correlates with response cost not reward of hypothalamic stimulation. Behav Brain Res. 2002;137(1-2):129-138.
24. Papp M, Klimek V, Winner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl). 1994;115(4);441-446.
25. Spyraki C, Fibiger HC. Behavioural evidence for supersensitivity of postsynaptic dopamine receptors in the mesolimbic system after chronic administration of desipramine. Eur J Pharmacol. 1981;74(2-3):195-206.
26. Ichikawa J, Meltzer HY. Effect of antidepressants on striatal and accumbens extracellular dopamine levels. Eur J Pharmacol. 1995;281(3):255-261.
27. Park SK, Nguyen MD, Fischer A, et al. Par-4 links dopamine signaling and depression. Cell. 2005;122(2):275-287.
28. Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997;12(suppl 3):7-14.
29. Sullivan PF, Neale MC. Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000;157(10):1552-1562.
30. Haeffel GJ, Getchell M, Koposov RA, et al. Association between polymorphisms in the dopamine transporter gene and depression: evidence for a gene-environment interaction in a sample of juvenile detainees. Psychol Sci. 2008;19(1):62-69.
31. Togsverd M, Werge TM, Tan ko LB, et al. Association of a dopamine beta-hydroxylase gene variant with depression in elderly women possibly reflecting noradrenergic dysfunction. J Affect Disord. 2008;106(1-2):169-172.
32. Jimerson DC. Role of dopamine mechanisms in affective disorder. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Rress; 1987:505-511.
33. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology. 1995;12(3):185-219.
34. Jouvent R, Abensour P, Bonnet AM, Widlocher D, Agid Y, Lhermitte F. Antiparkinsonian and antidepressant effects of high doses of bromocriptine. An independent comparison. J Affect Disord. 1983;5(2):141-145.
35. Corrigan MH, Denahan AQ, Wright CE, Ragual RJ, Evans DL. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety. 2000;11(2):58-65.
36. Dailly E, Chenu F, Renard CE, Bourin M. Dopamine, depression and antidepressants. Fundam Clin Pharmacol. 2004;18(6):601-607.
37. Serra G, Collu M, D'Aquila PS, Gessa GL. Role of the mesolimbic dopamine system in the mechanism of action of antidepressants. Pharmacol Toxicol. 1992;71(suppl 1):72-85.
38. Poewe W. Depression in Parkinson's disease. J Neurol. 2007;254(suppl 5):49-55.
39. Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson's disease: a national multicentre prospective randomized study. Eur J Neurol. 2003;10(4):399-406.
40. Barone P, Scarzella L, Marconi R, et al. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601-607.
41. Leentjens AF, Vreeling FW, Luijckx GJ, Verhey FR. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry. 2003;18(6):552-554.
42. Weintraub D, Morales KH, Moberg PJ, et al. Antidepressant studies in Parkinson's disease: a review and meta-analysis. Mov Disord. 2005;20(9):1161-1169.
43. Wermuth L, Sørensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram. Nord J Psychiatry. 1998;52:163-169.
44. Avila A, Cardona X, Martin-Baranera M, et al. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial. J Clin Psychopharmacol. 2003;23(5):509-513.
45. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology. 2000;55(8):1216-1218.
46. Tesei S, Antonini A, Canesi M, Zecchinelli A, Mariani CB, Pezzoli G. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord. 2000;15(5):986-989.
47. Bayulkem K, Torun F. Therapeutic efficiency of venlafaxin in depressive patients with Parkinson's disease. Mov Disord. 2002;17(suppl 5):204.
48. Okun MS. Watts RL. Depression associated with Parkinson's disease: clinical features and treatment. Neurology. 2002;58(4 suppl 1):63-70.
49. Paterson NE, Markou A. Animal models and treatments for addiction and depression co-morbidity. Neurotox Res. 2007;11(1):1-32.
50. Tremblay LK, Naranjo CA, Cardenas L, Herrmann N, Busto UE. Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine. Arch Gen Psychiatry. 2002;59(5):409-416.
51. Marinelli M, Piazza PV. Interaction between glucocorticoid hormones, stress and psychostimulant drugs. Eur J Neurosci. 2002;16(3):387-394.
52. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. J Clin Psychopharmacol. 1999;19(1):67-85.
53. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6)724-763.
54. Russo-Neustadt AA, Chen MJ. Brain-derived neurotrophic factor and antidepressant activity. Curr Pharm Des. 2005;11(12):1495-1510.
55. Castren E. Neurotrophic effects of antidepressant drugs. Curr Opin Pharmacol. 2004;4(1):58-64.
56. Sapolsky RM. Is impaired neurogenesis relevant to the affective symptoms of depression? Biol Psychiatry. 2004;56(3):137-139.
57. Russo-Neustadt AA, Alejandre H, Garcia C, Ivy AS, Chen MJ. Hippocampal brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, and physical exercise. Neuropsychopharmacology. 2004;29(12):2189-2199.
58. Tardito D, Perez J, Tiraboschi E, Musazzi L, Racagni G, Popoli M. Signaling pathways regulating gene expression, neuroplasticity, and neurotrophic mechanisms in the action of antidepressants: a critical overview. Pharmacol Rev. 2006;58(1):115-134.
59. Volkow ND, Wang GJ, Fowler JS, et al. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry. 2005;57(6):640-646.
60. Shaw AM. Boules MM, Williams K, Robinson J, Carlier PR, Richelson E. Antidepressant-like effects of PRC200, a novel norepinephrine, serotonin, and dopamine reuptake inhibitor [abstract]. Biol Psychiatry. 2006;59(8):61S.
61. Skolnick P, Popik P, Janowsky A, Beer B, Lippa AS. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol. 2003;461(2-3):99-104.
62. Popik P, Krawczyk M, Golembiowska K, et al. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677. Cell Mol Neurobiol. 2006;26(4-6):857-873.
63. Tatsumi M, Groshan K, Blakely RD, Richelson E. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997;340(2-3):249-258.
64. Shaw AM, Boules M, Zhang Y, et al. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050. Eur J Pharmacol. 2007;555(1):30-36.
65. McMillen BA. Shank JE, Jordan KB, Williams HL, Basile AS. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat. Alcohol Clin Exp Res. 2007;31(11):1866-1871.
66. Chen Z, Skolnick P. Triple uptake inhibitors: therapeutic potential in depression and beyond. Expert Opin Investig Drugs. 2007;16(9):1365-1377.
67. Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs. 2001;2(11):1592-1594.
68. Larsen MH, Rosenbrock H, Sams-Dodd F, Mikkelsen JD. Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine. Eur J Pharmacol. 2007;555(2-3):115-121.
69. Hauser RA, Salin L, Juhel N, Konyago VL. Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease. Mov Disord. 2007;22(3):359-365.
70. Zhou J, He R, Johnson KM, et al. Piperidine-based nocaine/modafinil hybrid ligands as highly potent monoamine transporter inhibitors: efficient drug discovery by rational lead hybridization. J Med Chem. 2004;47(24):5821-5824.